Bio-Techne appoints Steve Crouse as DSS President effective March 1; McManus transitions out

BIO-TECHNE Corp

Dr. Matt McManus will transition from President, Diagnostics and Spatial Biology Segment effective March 1, 2026, and remain to support transition.
Steve Crouse, previously SVP of Analytical Solutions, named successor; he joined in 2022 from Thermo Fisher Scientific.
Crouse's employment agreement includes base salary of $505,000, target cash bonus of 75% of base, and equity awards valued at ~$170,000 one-time and ~$1.2M annual target.
McManus's termination approved without cause; he will receive severance per employment agreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.